Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From General Electric
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.
The lack of availability of coronavirus vaccines in many less well off parts of the world is an open invitation to criminals seeking to sell falsified or substandard versions. Many instances of vaccine theft and diversion have also been found.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
- Medical Devices
- Other Names / Subsidiaries
- Clarient Inc.
- Asymptote Limited
- GE Healthcare
- GE Medical Systems LLC
- Monica Healthcare
- Novia Strategies
- Vital Signs.